Robert Cabrera/LinkedIn
Sep 24, 2025, 15:57
Robert Cabrera & Colleagues Developed the ELISA-Based Folate Receptor Autoantibody Assay
Robert Cabrera, Associate Professor at Baylor College of Medicine, shared on LinkedIn:
“I (we) developed the ELISA-based folate receptor autoantibody assay in 2008 based on Rothenberg’s 2004 study on neurodevelopmental risks (NTDs).
Today, 17-21 years later, folate receptor autoantibodies were mentioned in a US Presidential press conference on autism, which included Tylenol (acetaminophen) risks, and proposed treatment with reduced folate (folinic acid, leucovorin).”
Title: Autoantibodies to folate receptor during pregnancy and neural tube defect risk
Authors: Robert M Cabrera, Gary M Shaw, Johnathan L Ballard, Suzan L Carmichael, Wei Yang, Edward J Lammer, Richard H Finnell

Read more here.
Stay updated with Hemostasis Today.
acetaminophen
Autoantibody
Baylor College of Medicine
Edward J Lammer
ELISA
folinic acid
Gary M Shaw
Health
Hematology
Hemostasis
Hemostasis Today
Johnathan L Ballard
leucovorin
Medicine
neural tube defect
Neurodevelopmental Risks
Pregnancy
Richard H Finnell
Robert M Cabrera
Suzan L Carmichael
thrombosis
Tylenol
Wei Yang
-
Jul 12, 2026, 20:44Mary Cushman: Starting ISTH 2026 With Women’s Thrombosis and Hemostasis Health
-
Jul 12, 2026, 20:43Elif Güler Kazanci: Honored to Attend ISTH 2026
-
Jul 12, 2026, 20:41Anna Waterhouse: Exciting First Day at the ISTH 2026
-
Jul 12, 2026, 20:39Ghadir Alkarithi: Exploring the Latest Advances at ISTH 2026
-
Jul 12, 2026, 20:21Rainer Kaiser: How T Cells Boost Myeloid Effector Functions in Endocarditis
-
Jul 12, 2026, 17:04Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026